Search PubMed⌕ Search

Biomedical subjects

L Evangelisti

Publications and source records attributed to L Evangelisti.

6 recordsLinked to original sources
PubMed1992

[Ticlopidine and platelet function].

In macular degeneration disease of the eye, we have studied the behaviour of vitro thrombocyte aggregation/deaggregation and ex vivo plasma beta-thromboglobulin level (Born aggregometer, RIA kit) during administration of an antiaggregant platelet drug (ticlopidine). We have observed the presence of a prothrombotic state that improves after 15 days of administration of drug. In fact platelet aggregation and beta-thromboglobulin level significantly decrease while thrombocyte deaggregation significantly increase. The correlations between deaggregation, aggregation and beta-thromboglobulin level suggest that the antiaggregant action of the ticlopidine is linked to the inhibition of platelet release reaction.

Adult↗
PubMed1992

[Lipid behavior during hemodialysis using heparin and prostacyclin].

Ten patients have been studied for lipidic behaviour during hemodialysis using as anticoagulant heparin and prostacyclin. Hearing has been administered at infusion rate of 2000 U/h and prostacyclin in 5 ng/kg/min. Lipidic behaviour (before and after hemodialysis) has been studied for apolipoproteins A and B, total serum cholesterol and serum triglycerides, HDL-cholesterol, lipoprotein. Total serum cholesterol/HDL-cholesterol, apolipoproteins A/apolipoproteins B, apolipoproteins A/HDL-cholesterol ratios have been also studied. Our findings show that heparin produces acute changes in lipidic behaviour after hemodialysis and suggest that administrations may contribute to lipidic derangement of uremic dialytic patient while heparin free dialysis (prostacyclin infusion) doesn't show lipidic derangement after dialytic treatment. Prostacyclin infusion suggests that may be a useful anticoagulant and therapeutic drug especially in uremic dialytic subject with high atherosclerosis involvement, dyslipidemia and arterial hypertension.

Adult↗
PubMed1991

[Heparin anticoagulant activity: new knowledge and future prospects].

The present knowledge about the heparin molecular structure has been reported by current scientific literature and especially the relationship between structure and function. From the pharmacological point of view the authors suggest future lines of research in this field. The role of endothelial and the mechanisms of heparin removal from the circulation (saturation and desaturation) are analyzed. From the anticoagulation point of view the authors after the analysis of the anti-thrombin III and anti-factor Xa activity, evaluate the heparin biological action on the platelets, complement, white blood cells. They also evaluate the questions collected to heparin use in non classical clinical situations, alternative routes of administration and new therapeutic and anticoagulant procedure; the association of prostacyclin together with heparin.

Animals↗
PubMed1991

[Risk of disseminated intravascular coagulation in patients undergoing echo-guided transperineal prostatic needle biopsy with transrectal probe].

Disseminated intravascular coagulation (DIC) is a severe life-threatening acute bleeding disorder. Traumatized tissues, tumors, necrotic tissues, or bacterial endotoxines release similar material in the blood to the tissutal factors activating the coagulation cascade. This preliminary study was aimed at verifying the risk of DIC in patients undergoing US-guided transperineal prostatic biopsy with Chiba and Tru-Cut needles. To evaluate the activation degree of coagulation factors in the circulation, the authors measured the concentrations of urinary fibrin degradation products in 10 patients undergoing US-guided transperineal prostatic biopsy, both before and after biopsy, every second hour, for 24 hours. Every tube of urine sample contained soya bean trypsin inhibitor and bovine thrombin to prevent any further fibrin degradation during incubation period for the possible presence of blood in urine samples. The results showed that 7/10 patients had marked increase in urinary fibrin degradation product levels (up to 800 micrograms%), with a 3-phase trend: early peak after 2-6 hours, middle peak after 6-14 hours, and late peak after 18-24 hours, which proved the activation of the coagulation cascade.

Aged↗
PubMed1989

Heparin and prostacyclin.

Hemodialysis performed with prostacyclin (5 ng/kg/min) as a substitute for heparin was studied in 10 patients. The subjects were studied during heparin perfusion alone and during heparin perfusion together with prostacyclin. The authors investigated the effect of two heparin regimens (regimen I: 2,000 U/hr and regimen II: 500 U/hr) upon plasma antithrombin level (IU/mL) and activated thromboplastin time (sec). Our findings show: (1) prostacyclin can substitute for heparin anticoagulation in hemodialysis; (2) the concomitant administration of prostacyclin enhances the anticoagulant effect of heparin, based on the measurement of the activated partial thromboplastin time; (3) the antithrombin activity is increased by both treatments but more so with prostacyclin; and (4) platelet activation plays a role in limiting heparin anticoagulation, a conclusion partly supported by the finding that activated partial thromboplastin time is somewhat more prolonged by heparin when measured in platelet-poor rather than in platelet-rich plasma in the presence of prostacyclin. Physiopathologic implications of these preliminary findings are discussed.

Adult↗